“A Single Step Process For The Preparation Of Omadacycline Tosylate Of Formula (X)”

Sumar Biotech Llp
Reply Not Filed App No 202321074089 Chemical

Patent information

IP India · live record
Application number
202321074089
Filing date
31 October 2023
Status
Reply Not Filed
Publication number
09/2024
Publication type
INA
Invention field
Chemical

Abstract

ABSTRACT The present invention relates to a process for the preparation of Omadacycline tosylate of formula (X). More particularly, the present invention relates to a single step process for the preparation of omadacycline tosylate of formula (X) in which the single step process starts with using minocycline hydrochloride of formula (1) as starting material and give final omadacycline tosylate of formula (X) without isolating any intermediate of the process.

Applicants

1
India
Sumar Biotech LLP Plot No.: 112, 113, 114, G.I.D.C. Estate, Tal: Gozaria, Dist: Mehsana-382825, Gujarat, India.

Inventors

9
India
Tarunkumar AkhajaC/O: Sumar Biotech LLP Plot No.: 112, 113, 114, G.I.D.C. Estate, Tal: Gozaria, Dist: Mehsana-382825, Gujarat, India.
India
Naresh Ranaji KiriC/O: Sumar Biotech LLP Plot No.: 112, 113, 114, G.I.D.C. Estate, Tal: Gozaria, Dist: Mehsana-382825, Gujarat, India.
India
Dr. Rakesh Kumar AmetaDepartment of Chemistry, Sri M M Patel Institute of Sciences and Research, Kadi Sarva Vishwavidyalaya, Gandhinagar-382023, Gujarat, India.
India
Patel Akshaykumar MukeshbhaiC/O: Sumar Biotech LLP Plot No.: 112, 113, 114, G.I.D.C. Estate, Tal: Gozaria, Dist: Mehsana-382825, Gujarat, India.
India
Thakor Nileshkumar BalajiC/O: Sumar Biotech LLP Plot No.: 112, 113, 114, G.I.D.C. Estate, Tal: Gozaria, Dist: Mehsana-382825, Gujarat, India.
India
Patel Harshilkumar ShaileshbhaiC/O: Sumar Biotech LLP Plot No.: 112, 113, 114, G.I.D.C. Estate, Tal: Gozaria, Dist: Mehsana-382825, Gujarat, India.
India
Sunny Nitinkumar PatelC/O: Sumar Biotech LLP Plot No.: 112, 113, 114, G.I.D.C. Estate, Tal: Gozaria, Dist: Mehsana-382825, Gujarat, India.
India
Keyurkumar Arjanbhai KamaniChemistry Department, Bahauddin Science College, College Road, Junagadh-362001, Gujarat, India.
India
Jignesh Priyakant RavalB-1, #303, Maple Oasis, Behind Pooja Bunglow, Near Shreejy Granary, Karamsad - Vidya Nagar, Karamsad - 388325 Dist: Anand, Gujarat

Claims

4
1 A single step process for the preparation of omadacycline tosylate of formula (X) comprises the steps: i. Reacting minocycline hydrochloride of formula (1) with Nhydroxymethyl phthalimide of formula (2) in presence of p10 toluene sulphonic acid in 5-20 volumes of alcoholic solvent at a temperature between 250C to 800C to give tris protected minocycline of formula (3) in alcoholic solvent; ii. Adding 10 to 15 volumes of ethylene diamine at a temperature between 00C to 100C to get pH between 8.5 to 15 9.5 followed by removal of solid mass through filtration and distilling alcoholic solvent to get oily mass of compound of formula (4); iii. Adding 5 to 15 volumes of ethyl acetate, 0.5 to 1 volume of pilvadehyde of formula (5), and 5% platinum oxide (PtO2) 20 into oily mass of compound of formula (4) and stirring the reaction mass at a temperature between 200C to 400C under continuous passing of hydrogen gas at a pressure between 0.5 to 0.8 psi for 5 to 7 hours followed by removal of Platinum oxide (PtO2) from the reaction mass and 25 adjusting pH between 8-9 using ehthylenediamine to give omadacycline free base of formula (6) in ethyl acetate solvent; iv. Adding 0.5 to 1 mole ratio of p-toluene sulphonic acid (pTSA) to adjust pH between 3.5 to 4.5 and stirring it at a 30 temperature between 00C to 100C followed by filtration to give Omadacycline tosylate of formula (X).
2 The process for the preparation of omadacycline tosylate of formula (X) as claimed in claim-1 wherein in step-i, alcoholic solvent is selected from methanol, ethanol or Isopropyl alcohol 35 (IPA).
3 The process for the preparation of omadacycline tosylate of formula (X) as claimed in claim-1 wherein in step-i, minocycline Page 17 of 17 5 HCl of formula (1): N-hydroxymethyl phthalimide (2): p-toluene sulphonic acid (pTSA) is taken in a mole ratio between 1:2- 4:0.03-0.1.
4 The process for the preparation of omadacycline tosylate of formula (X) as claimed in claim-1 wherein after completion of 10 step-iii, water wash and charcoal treatment is given to the ethyl acetate filtrate.

Specification

Show full textCollapse

FORM 2 THE PATENTS ACT, 1970 (Act 39 of 1970) COMPLETE SPECIFICATION (See Section 10; Rule 13) 10 Title: “A single step process for the preparation of 15 omadacycline tosylate of formula (X)” 20 Applicants: SUMAR BIOTECH LLP 25 Address: Plot No.: 112, 113, 114, G.I.D.C. Estate, Tal: Gozaria, Dist: Mehsana-382825, Gujarat, India. 30 35 Nationality: An Indian Company 40 45 The following specification describes the nature of the invention and the manner in which it is to be performed: Page 2 of 17 5 FIELD OF THE INVENTION The present invention relates to a process for the preparation of Omadacycline tosylate of formula (X). More particularly, the present invention relates to a single step process for the preparation of omadacycline tosylate of formula (X) in which the single step process 10 starts with using minocycline hydrochloride of formula (1) as starting material and give final omadacycline tosylate of formula (X) without isolating any intermediate of the process.

N N H H OH NH2 OH O OH O O OH .HCl S O O OH H N O OH OH O OHOH O NH2 N N Formula (1) Formula (X) 15 BACKGROUND OF THE INVENTION Omadacycline tosylate of formula (X) is a compound selected from group of 9-aminomethyl substituted minocycline compounds, a class of tetracycline antibiotic compounds. Omadacycline tosylate of 20 formula (X) is used for the treatment of community acquired bacterial pneumonia infections and acute bacterial skin infections caused by susceptible microorganisms. S O O OH H N O OH OH O OHOH O NH2 N N Formula (X) 25 It is also known by its IUPAC name (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-9-[(2,2-dimethylpropyl amino)methyl]-1,10,11,12atetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;4-methylbenzene sulfonic acid. Omadacycline tosylate may be represented with the chemical formula 30 (X). The current synthesis of omadacycline, depicted in Scheme-1, has been used for multi-kilogram preparations and is described in US 9434680 B2. Minocycline has several reactive functional groups and the C2 primary 35 amide is more reactive towards electrophiles than C9 or the C10. Due to this fact, the first step of Scheme-1 requires nearly three equivalents of the N’-(hydroxymethyl)-phthalimide in triflic acid yielding a bissubstituted aminomethyl phtalimide tetracycline compound. In the second step of Scheme-1, the phthalimides are de-protected with a Page 3 of 17 5 large excess of methylamine in alcoholic solution to afford a bissubstituted aminomethyl tetracycline intermediate. Scheme-1: Synthesis of omadacycline using minocycline as substrate and N’-(hydroxymethyl) phtalimide as reagent: 10 In the third step of Scheme-1, the resulting intermediate is reacted with hydrogen under hydrogenation conditions to form a C9- 15 substituted aminomethyl tetracycline intermediate. In the fourth step of Scheme-1, the formed compound is reacted with pivaldehyde under hydrogenation conditions to afford omadacycline. After reverse-phase chromatographic purification, pH adjustment and precipitation the desired product is afforded as an amorphous, unstable solid. For a 20 long-term manufacturing route, the challenges of the instability of the aminomethyl intermediate and chromatographic column purification step must be overcome. WO2022248865A1 has disclosed a process for the preparation of 9- 25 aminomethyl tetracycline compounds including omadacycline and its salt wherein semicontinuous and continuous flow processes have been disclosed. In a continuous flow process as disclosed in the said patent, the whole synthetic sequence of the method of the present invention may be 30 carried out from the minocycline reacted in step a) to the 9-aminomethyl tetracycline compound formed in step d) without the use of batch reactors, without the need to isolate the 9-aminomethyl tetracycline intermediate formed in step b) and in the absence of a hydrogenation reaction prior to step c) or d). Alternatively, in a semi 35 continuous flow process, two of steps a), b) and c) or d) may be carried without the use of batch reactors, without the need to isolate Page 4 of 17 5 intermediate products between the reaction steps. The steps a) and b) of the method of the present invention may operate in a continuous manner, steps b) and c) of the method of the present invention may operate in a continuous manner, or steps b) and d) of the method of the present invention may operate in a continuous manner. Where 10 steps b) and c) or steps b) and d) operate in a continuous manner, the 9-aminomethyl tetracycline intermediate formed in step b) may be used directly in step c) or d). According to the said patent, continuous flow technologies use process intensification (e.g. high temperatures and pressure) and improved 15 mass and heat transfer to increase selectivity and overcome the challenges of purification, low yields and the isolation of an unstable intermediate. It has been found that it is possible to synthesize a 9-aminomethyl tetracycline intermediate directly from 2,9-(methylamidesubstituted) minocycline compound by using higher temperatures that 20 are only feasible by using flow chemistry technologies at low residence time. In the above patent, the process of all steps including step a to d, is carried out at a higher temperature up to 3000C and a pressure up to 500 psi, the higher temperature and higher pressure may cause major 25 industrial accidents and damages to human beings, properties and hence is not a commercially viable process. Scheme-2: Impurities formed in the first step (Reaction between Minocycline HCl and N-hydroxymethyl phthalimide): 30 As shown in scheme-2 and as disclosed in the prior art methods, in the reaction between minocycline Hcl and N-hydroxymethyl phthalimide, 2-substituted, 9-substituted, and tri-substituted Page 5 of 17 5 compounds are also formed as impurities along with bis-substituted compound of formula (3) and the proportion of those compounds/impurities are not small. Among above all, only bissubstituted compound of formula (3) is useful in preparation of omadacyline tosylate. 10 The 2-position substitution impurity cannot be changed into a next product through a subsequent process, but becomes a starting material and cannot be recycled, so that the raw material is wasted, and the 9-position substitution and the tri-position substitution can be converted into a product in the next process, but the reaction time 15 is prolonged, and the production cost is also increased. Hence, there is a demand of providing a simple, easy to operate, industry & economically viable and environment friendly, single step process for the preparation of omadacycline tosylate of formula (X) 20 from minocycline hydrochloride of formula (1). Applicant has found that the proposed processes for the preparation of omadacycline tosylate of formula (X) provide increased yield of omadacycline tosylate of formula (X) with improved quality having lesser amounts of impurities in the final product. 25 OBJECTS OF THE INVENTION Accordingly, the main object of the present invention is to overcome the problems faced by the prior art processes in the preparation of omadacycline tosylate of formula (X). 30 There is an object of the present invention to provide a simple, environment friendly, robust, easy to operate, industry & economically viable and single step environment friendly process for the preparation of omadacycline tosylate of formula (X) from minocycline 35 hydrochloride of formula (1). It is also an object to provide a process for the preparation of omadacycline tosylate of formula (X) from minocycline hydrochloride of formula (1) that provides increased yield of omadacycline tosylate of 40 formula (X) with improved quality having lesser amounts of impurities in the final product. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a single step process for the 45 preparation of omadacycline tosylate of formula (X) in which the single step process starts with using minocycline hydrochloride of formula (1) as starting material and give final omadacycline tosylate of formula Page 6 of 17 5 (X) without isolating the intermediate in any of the steps of the process.

N N H H OH NH2 OH O OH O O OH .HCl S O O OH H N O OH OH O OHOH O NH2 N N Formula (1) Formula (X) 10 Proposed Route of synthesis along with the brief process for the preparation of omadacycline tosylate of formula (X) is shown as follows: Scheme-3: Route of Synthesis for Preparation of omadacycline tosylate of formula (X): N N H H OH NH2 OH O OH O O OH N O O OH N N H H O O OH O OH N O O OH HN O O O N N H H OH O OH O OH H2N OH NH2 . O HCl N O O 1 minocycline hydrochloride 3 H N O OH OH O OH OH O NH2 N N 6 omadacycline free base S O O OH H N O OH OH O OH OH O NH2 N N X omadacycline tosylate O 5 2 4 PTSA EthyleneDiamine Ethylenediamine PtO2 PTSA 15 The present invention provides a simple, environment friendly, robust, easy to operate, industry & economically viable and single step process for the preparation of omadacycline tosylate of formula (X) 20 from minocycline hydrochloride of formula (1). The present innovators have comprehensively and successfully investigated the possibility of developing a single step process for the preparation of omadacycline tosylate of formula (X). Page 7 of 17 5 The major differences between the Route of synthesis and process of the present invention as per the scheme-3 and in the prior art methods are as follows: (i) In the present invention, the whole process is carried out as a single step process and no intermediates of any step is isolated and 10 carried forward directly for the next step until the final omadacycline tosylate of formula (X) is obtained. (ii) p-toluene sulphonic acid (PTSA) is used in the present invention in place of methane sulphonic acid, triflic acid or sulfuric acid in the first step, p-toluene sulphonic acid is not reported in any of the prior 15 art processes. (iii) Ethylenediamine is used in place of methyl amine in the second step, ethylenediamine is not reported in any of the prior art processes. (iv) ethylenediamine is used in place of triethyl amine in the third 20 step, Ethylenediamine is not reported in any of the prior art processes. (v) platinum oxide (PtO2) is used as hydrogenating agent, platinum oxide is not reported in any of the prior art processes. 25 Methyl amine which is reported in the prior art processes, is included in List 1 precursor due to its use in methamphetamine narcotic drug hence the use of methylamine should be done under strict observation. Methyl amine is gaseous in nature and is available in gaseous form or as % molar solution in methanol, ethanol, water or 30 Tetrahydrofuran. Use of molar solution of methyl amine in the reaction may increase the complexity due to its solution in any of the above listed solvents which actually, may not a part of the reaction and additional activity like distillation, filtration, washing etc. is required to be carried out after completion of the reaction that makes 35 the process lengthy and tedious. Further, due to its gaseous nature, methylamine may escape from the reaction easily hence either more quantity of methyl amine is required or reaction has to carried out at a temperature near to 00C to maintain the pH of the reaction mass to complete the reaction. Also, due to escape of methyl amine from the 40 reaction, pH of reaction mass differs which lead to incomplete reaction or it may lead to impurities as described above. Also, methyl amine in the reaction is not recyclable and for every reaction process, fresh methyl amine has to be used which may create environmental issues. 45 While ethylenediamine used in the present invention, is a liquid in nature having boiling point of 1160C that makes easy to maintain pH of the reaction mass throughout the reaction even at a temperature Page 8 of 17 5 between 200C to 800C and thus ethylenediamine plays an important role in completion of the reaction. It is also possible that ethylene diamine can be recovered and may be used in the reaction again. Thus, recycling of ethylenediamine may reduce the environmental issues. 10 Methane sulphonic acid, triflic acid and sulfuric acid are strong acids have been used in the prior art processes, all are liquid in nature hence utmost care has to be taken while using either of two in the reaction process or handling it or storing it as chemical. While p15 toluene sulphonic acid (PTSA) used in the present invention is also a strong acid but solid in nature hence the weighing it for reaction purpose or storing it as chemical is much easier than methane sulphonic acid, triflic acid or sulfuric acid. 20 According to the present invention, a single step process for the preparation of omadacycline tosylate of formula (X) is provided, the said process comprises: i. Reacting minocycline hydrochloride of formula (1) with Nhydroxymethyl phthalimide of formula (2) in presence of p25 toluene sulphonic acid in alcoholic solvent at a temperature between 250C to 800C to give tris protected minocycline of formula (3) in alcoholic solvent; ii. Adding ethylene diamine at a temperature between 00C to 100C to get pH between 8.5 to 9.5 followed by removal of solid mass 30 through filtration and distilling alcoholic solvent to get oily mass of compound of formula (4); iii. Adding ethyl acetate, pilvadehyde of formula (5), and 5% platinum oxide (PtO2) into oily mass of compound of formula (4) and stirring the reaction mass at a temperature between 200C to 35 400C under continuous passing of hydrogen gas at a pressure between 0.5 to 0.8 psi for 5 to 7 hours followed by removal of Platinum oxide (PtO2) from the reaction mass and adjusting pH between 8-9 using ehthylenediamine to give omadacycline free base of formula (6) in ethyl acetate solvent; 40 iv. Adding p-toluene sulphonic acid to adjust pH between 3.5 to 4.5 and stirring it at a temperature between 00C to 100C followed by filtration to give Omadacycline tosylate of formula (X). Now, each step of a single step is explained as follows: Step-i: 45 The role of temperature, addition of p-toluene sulphonic acid, Nhydorxymethyl phthalimide is important to increase the percentage Page 9 of 17 5 (%) formation of tris protected minocycline of formula (3) and to eliminate or to reduce the percentage (%) formation of mono and bis protected minocycline hence the reaction is carried out at a temperature between 250C to 800C. Minocycline HCl of formula (1): N-hydroxymethyl phthalimide (2): p10 toluene sulphonic acid is taken in a mole ratio between 1:2-4:0.03- 0.1. Alcoholic solvent is added in a volume between 5 to 20 volumes for proper mixing of the reaction mass. Alcoholic solvent is selected from but not limited to methyl alcohol (MeOH), ethyl alchol (EtOH) or 15 isopropyl alchohol (IPA). During the reaction of step-i, online HPLC analysis is carried out, it confirms that in step-i, tris protected minocycline of formula (3) is obtained as a major product while mono and bis protected minocycline is obtained in about 2-5% after completion of the 20 reaction. After completion of the reaction of step-i, tris protected minocycline of formula (3) which is in the alcoholic solvent is further taken for step-ii. It is to be noted here that the tris protected minocycline of formula (3) 25 may be taken for step-ii with or without isolation of it. More preferably, tris protected minocycline of formula (3) may be taken for step-ii without isolation as it will save time, men power and resources. While conducting step-ii, there is no need to transfer the reaction 30 mass and the same vessel or apparatus may be used for carrying out step-ii. Step-ii: In the reaction, ethylene diamine is added in excess volume to the alcoholic reaction mass containing tris protected minocycline of 35 formula (3). The volume of ethylene diamine is kept between 10 to 15 volumes by adjusting pH between 8.5 to 9.5. The selection of ethylene diamine replaces methyl amine use in the reaction. The whole reaction is carried out at a temperature between 00C to 100C. 40 Use of ethylene diamine, volume of ethylene diamine, pH and temperature play an important role in step-ii. If volume of ethylene diamine or temperature range or pH range is higher or lower than the decided range, it will give undesired products or impurities that will ultimately decrease the quality and quantity of the obtained 45 compound of formula (4). Page 10 of 17 5 After completion of the reaction of step-ii, solid mass is removed through filtration and filtrate containing alcoholic solvent is removed using vacuum distillation at a temperature between 30-450C. During vacuum distillation, excess of ethylene diamine is also removed along with alcohol. 10 After distilling out alcoholic solvent completely from step-ii, oily mass containing compound of formula (4) is further taken for hydrogenation reaction i.e. step-iii. Step-iii: 15 Step-iii is carried out in the pressure reaction vessel. The reaction vessel is degassed by passing nitrogen gas and ensures the absence of oxygen gas in the reaction vessel. The oily mass containing compound of formula (4) is transferred to the pressure reaction vessel. Ethyl acetate, pilvadehyde of formula (5), and 5% platinum oxide (PtO2) is 20 added into oily mass of compound of formula (4) and stirred the reaction mass at a temperature between 200C to 400C under continuous passing of hydrogen gas at a pressure between 0.5 to 0.8 psi for 5 to 7 hours. After completion of the reaction, Platinum oxide (PtO2) is removed from 25 the reaction mass through filtration. Ethylene diamine is added to the filtrate to adjust pH between 8 to 9 which will give omadacycline free base of formula (6) in ethyl acetate solvent. In the above step-iii, ethyl acetate is used in a volume between 5 to 15 30 volumes and pivaldehyde of formula (5) is added in 0.5 to 1 volume. The said ethyl acetate filtrate containing omadacycline free base of formula (6) is washed with water several times. Charcoal treatment at a temperature between 40 to 500C is given to the ethyl acetate filtrate 35 to remove undesired impurities, unreacted pivaldehyde and ethylene diamine from ethyl acetate filtrate. The treated ethyl acetate filtrate containing omadacycline free base of formula (6) is taken for next step-iv. 40 Step-iv: The reaction is carried out in same solvent and tosylate salt of omadacycline is prepared using p-toluene sulphonic acid (p-TSA) at a pH between 3.5 to 4.5. The addition of p-toluene sulphonic acid (p-TSA) is crucial and it 45 should be added in a quantity to adjust the pH of the reaction mass between 3.5 to 4.5. pH and temperature play an important role in Page 11 of 17 5 formation and isolation of the final Omadacycline tosylate of formula (X). After addition of 0.5 to 1 mole ratio of p-toluene sulphonic acid (pTSA), the reaction mass is stirred at a temperature between 00C to 100C and filtered it to give Omadacycline tosylate of formula (X). 10 After completion of the reaction, the reaction mass is filtered and washed with solvent selected from water, methanol, ethanol or methyl t-butyl ether (MTBE) to give pure omadacycline tosylate of formula (X). Optionally, the reaction mass may also be taken further for 15 purification as per the prior art processes to obtain pure omadacycline tosylate of formula (X). The Omadacycline tosylate of formula (X) obtained with the said process is having HPLC purity between 98% to 99.8% including 20 tautomer of it. EXAMPLES: A single step process for the preparation of Omadacycline tosylate of formula (X) as per Scheme-3: 25 Minocycline hydrochloride of formula (1) is added to the alcoholic solvent followed by addition of p-toluene sulphonic acid (PTSA) and Nhydroxymethyl phthalimide of formula (2) at a temperature between 25-30°C, heated to 60-80°C and stirred for 10 to 12 hrs at the same temperature to get mixture of mono, bis and tris protected minocycline 30 of formula (3). The said mixture is cooled to 0-5°C and adjusted pH between 8.5 to 9.5 with the addition of ethylenediamine. The reaction mass is stirred at 0-100C for half an hour and filtered to remove the solid mass for the reaction mass. Reaction mass then taken for distillation to remove alcoholic solvent to get compound of formula (4) 35 as an oily mass. Ethyl acetate is added in the said oily mass, and dried it over drying agent to remove moisture from the reaction mass. Transfer the reaction mixture to the pressure vessel and remove the oxygen completely from the pressure vessel by purging nitrogen gas into the vessel. Pivaldehyde of formula (5) is added in the said mass 40 followed by addition of hydrogenation catalyst 5% PtO2, the said mass is then carried forward for hydrogenation through passing of hydrogen gas at a pressure between 0.5 to 0.8 psi at a temperature between 20 to 30°C and stirred the mass for 5 to 7 hours along with continuous passing of hydrogen gas at the same temperature. After completion of 45 the reaction, filtered the reaction mass to get clear reaction mass followed by adjusting pH of the mass between 8 to 9 using ethylenediamine to give omadacycline free base of formula (6) in ethyl Page 12 of 17 5 acetate solvent. Water wash is given to the said mass followed by giving the charcoal treatment to the said mass at a temperature between 400C to 500C to remove the impurities, unreacted pivaldehyde and/or ethylenediamine. Omadacycline free base of formula (6) remained in ethyl acetate is further reacted with p-toluene sulphonic acid at a pH 10 between 3.5 to 4.5 and at a temperature between 0-100C followed by filtration and washing it with solvent to give omadacycline tosylate of formula (X). Following are the examples provided with comparative examples as 15 per the prior art processes for each step. Step-i: Preparation of compound of formula (3): Examples with different parameters are provided as follows: Sr. No. Minocycline Hcl (1) (mole ratio) Solvent and its volume Nhydorxymeth yl pthalimide (2) (mole ratio) AND reaction time Acid catalyst mole Ratio Tempe -rature (oC) HPLC result As per the process of the present invention 01 1 Methanol (10v) 2 (8 to 10 hrs) p-TSA (0.1) 40-60 Complies 02 1 Methanol (10v) 2 (8 to 10 hrs) p-TSA (0.1) 40-60 Complies 03 1 Ethanol (15v) 2.5 (8 to 10 hrs) p-TSA (0.1) 40-60 Complies 04 1 Ethanol (15v) 4 (8 to 10 hrs) p-TSA (0.04) 40-60 Complies 05 1 IPA (16) 4.75 (10 to 12 hrs) p-TSA 0.05 60-80 Complies 06 1 IPA (18) 4.75 (10 to 12 hrs) p-TSA 0.05 60-80 Complies As per Prior art Processes: 07 1 Toluene (15) 4 (10-15 hrs) H2SO4 (0.1) 50-70 Complies 08 1 Toluene (15) 4 (10-15 hrs) Me-SO3H (0.1) 50-70 Complies 09 1 Toluene (15) 4 (10-15 hrs) Triflic acid (0.1) 50-70 Complies Page 13 of 17 5 Step-ii: Preparation of compound of formula (4): Examples with different parameters are provided as follows: Sr. No. solvent Base (mole ratio) pH Time Temperature (oC) HPLC result As per the process of the present invention 01 ---- Ehtylene diamine (10) 6.5–7.8 15-20 minutes 10-20 Complies (90%) 02 ---- Ehtylene diamine (10) 6.5–7.1 15-20 minutes 10-20 Complies (90%) 03 ---- Ehtylene diamine (12) 8.5-9.5 30 minutes 0-10 Complies (92%) 04 ---- Ehtylene diamine (14) 8.5-9.5 30 minutes 0-10 Complies (92%) 05 ---- Ehtylene diamine (14) 8.5-9.5 30 minutes 0-10 Complies (92%) As per Prior art Processes: 06 methanol Methyl diamine (10) 5.5-6.5 30 minutes 20-30 Not complies 07 water Methyl diamine (10) 5.5-6.5 30 minutes 20-30 Not complies 08 --- Methyl diamine (12) 5.5-6.5 15-20 minutes 20-30 Not complies 09 --- Methyl amine (14v) 6.5-7.7 15-20 minutes 10-20 Not complies 10 Page 14 of 17 5 Step-iii: Preparation of omadacycline free base (6): Examples with different parameters are provided as follows: Sr. No. Solvent (Volume) Pivaldehyde (volume) Catalyst (%) Temp erature (oC) Base & pH HPLC result 01 Ethyl acetate (5) 0.5 PtO2 (5%) 20-30 Ethylene diamine (8-9) Complies (95%) 02 Ethyl acetate (10) 1 PtO2 (5%) 20-30 Ethylene diamine (8-9) Complies (95%) 03 Ethyl acetate (15) 0.5 PtO2 (5%) 20-30 Ethylene diamine (8-9) Complies (95%) 04 Ethyl acetate (5) 1 PtO2 (5%) 20-30 Ethylene diamine (8-9) Complies (95%) 05 Ethyl acetate (5) 0.8 PtO2 (5%) 20-30 Ethylene diamine (8-9) Complies (95%) As per Prior art Processes: 06 Ethanol (8) 1 Pd/C 0-10 Methylene diamine (5-6) Complies (48%) 07 Ethanol (10) 1 PtO2 20-30 Methylene diamine (7-8) Complies (50%) 08 Methanol (7) 1 PtO2 0-10 Methylene diamine (7-8) NA 09 Methanol (5) 1.5 PtO2 20-30 Methylene diamine (8-9) Complies (50%) 10 Toluene (4) 1.5 Pd/C 20-30 Methylene diamine (8-9) Complies (55%) 11 Toluene (8) 1.25 PtO2 10-20 Ammonia (7-8) Complies (56%) Page 15 of 17 12 THF (5.5) 05 PtO2 0-10 TEA (8-9) NA 5 Step-iv: Preparation of omadacycline tosylate (X): Examples with different parameters are provided as follows: (As per present invention): Sr. No. p-TSA (mole ratio) pH Temperature (oC) HPLC result (% purity) Yield of (X) (w/w) 01 0.6 1-2 20-30 Not complies ---- 02 0.8 2-3 0-10 90 0.4 03 0.8 2-3 0-10 95 0.4 04 0.8 3.5-4.5 0-10 97 0.5 05 0.75 3.5-4.5 0-10 98 0.6 10 ADVANTAGES OF THE PRESENT INVENTION 1. The process for the preparation of omadacycline tosylate of formula (X) is a single step process. 2. The process of the present invention is a simple, environment friendly, robust, easy to operate, industry & economically viable 15 process. 3. The said process provides increased yield of omadacycline tosylate of formula (X) with improved quality having lesser amounts of impurities in the final product. 20 Page 16 of 17 5 We claim: 1. A single step process for the preparation of omadacycline tosylate of formula (X) comprises the steps: i. Reacting minocycline hydrochloride of formula (1) with Nhydroxymethyl phthalimide of formula (2) in presence of p10 toluene sulphonic acid in 5-20 volumes of alcoholic solvent at a temperature between 250C to 800C to give tris protected minocycline of formula (3) in alcoholic solvent; ii. Adding 10 to 15 volumes of ethylene diamine at a temperature between 00C to 100C to get pH between 8.5 to 15 9.5 followed by removal of solid mass through filtration and distilling alcoholic solvent to get oily mass of compound of formula (4); iii. Adding 5 to 15 volumes of ethyl acetate, 0.5 to 1 volume of pilvadehyde of formula (5), and 5% platinum oxide (PtO2) 20 into oily mass of compound of formula (4) and stirring the reaction mass at a temperature between 200C to 400C under continuous passing of hydrogen gas at a pressure between 0.5 to 0.8 psi for 5 to 7 hours followed by removal of Platinum oxide (PtO2) from the reaction mass and 25 adjusting pH between 8-9 using ehthylenediamine to give omadacycline free base of formula (6) in ethyl acetate solvent; iv. Adding 0.5 to 1 mole ratio of p-toluene sulphonic acid (pTSA) to adjust pH between 3.5 to 4.5 and stirring it at a 30 temperature between 00C to 100C followed by filtration to give Omadacycline tosylate of formula (X). 2. The process for the preparation of omadacycline tosylate of formula (X) as claimed in claim-1 wherein in step-i, alcoholic solvent is selected from methanol, ethanol or Isopropyl alcohol 35 (IPA). 3. The process for the preparation of omadacycline tosylate of formula (X) as claimed in claim-1 wherein in step-i, minocycline Page 17 of 17 5 HCl of formula (1): N-hydroxymethyl phthalimide (2): p-toluene sulphonic acid (pTSA) is taken in a mole ratio between 1:2- 4:0.03-0.1. 4. The process for the preparation of omadacycline tosylate of formula (X) as claimed in claim-1 wherein after completion of 10 step-iii, water wash and charcoal treatment is given to the ethyl acetate filtrate.

Documents

Sign in to open
Application documents
1 202321074089-STATEMENT OF UNDERTAKING (FORM 3) [31-10-2023(online)].pdf 31 Oct 2023
2 202321074089-PROVISIONAL SPECIFICATION [31-10-2023(online)].pdf 31 Oct 2023
3 202321074089-POWER OF AUTHORITY [31-10-2023(online)].pdf 31 Oct 2023
4 202321074089-FORM FOR STARTUP [31-10-2023(online)].pdf 31 Oct 2023
5 202321074089-FORM FOR SMALL ENTITY(FORM-28) [31-10-2023(online)].pdf 31 Oct 2023
6 202321074089-FORM 1 [31-10-2023(online)].pdf 31 Oct 2023
7 202321074089-EVIDENCE FOR REGISTRATION UNDER SSI(FORM-28) [31-10-2023(online)].pdf 31 Oct 2023
8 202321074089-EVIDENCE FOR REGISTRATION UNDER SSI [31-10-2023(online)].pdf 31 Oct 2023
9 202321074089-DECLARATION OF INVENTORSHIP (FORM 5) [31-10-2023(online)].pdf 31 Oct 2023
10 202321074089-COMPLETE SPECIFICATION [20-01-2024(online)].pdf 20 Jan 2024
11 202321074089-FORM-9 [03-02-2024(online)].pdf 03 Feb 2024
12 202321074089-FORM 18 [03-02-2024(online)].pdf 03 Feb 2024
13 202321074089-Request Letter-Correspondence [23-10-2024(online)].pdf 23 Oct 2024
14 202321074089-Power of Attorney [23-10-2024(online)].pdf 23 Oct 2024
15 202321074089-FORM28 [23-10-2024(online)].pdf 23 Oct 2024
16 202321074089-Form 1 (Submitted on date of filing) [23-10-2024(online)].pdf 23 Oct 2024
17 202321074089-Covering Letter [23-10-2024(online)].pdf 23 Oct 2024
18 202321074089-CERTIFIED COPIES TRANSMISSION TO IB [23-10-2024(online)].pdf 23 Oct 2024
19 202321074089-Correspondence-Letter [30-10-2024(online)].pdf 30 Oct 2024
20 202321074089-FER.pdf 24 Oct 2025
Search strategy
1202321074089_SearchStrategyNew_E_202321074089E_08-10-2025.pdf